Skyrizi®
risankizumab-rzaa

An IL-23 inhibitor for adults with moderate to severe plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy and for adults with active psoriatic arthritis (PsA)[1]

For Ps & For PsA

ONLY 4 DOSES A YEAR AFTER INITIATION DOSES AT WEEKS 0 AND 4

RELIABLE 3-MONTH DOSING

INITIATION	MONTH 3	MONTH 6	MONTH 9	MONTH 12
				
WEEK 0 WEEK 4	WEEK 16	WEEK 28	WEEK 40	WEEK 52

ADMINISTERED BY A SINGLE 150 mg/mL SUBCUTANEOUS INJECTION

1 DOSAGE FOR ALL PATIENTS,

regardless of baseline weight, disease severity, or prior treatment.[1]

150 mg/mL
single-dose pen

OR



150 mg/mL single-dose
prefilled syringe

ADMINISTRATION INSTRUCTIONS[1]

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.

SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.

Skyrizi® COMPLETE

Help your patients start and stay on track with their prescribed treatment plan with Skyrizi Complete.

Visit SKYRIZIHCP.com to help your patients enroll

INDICATIONS[1]

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

SAFETY CONSIDERATIONS[1]

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Avoid use of live vaccines in SKYRIZI patients.

Please see additional Important Safety Information on the other side.
For more information, including Instructions for Use, please see accompanying Full Prescribing Information.

An IL-23 inhibitor for adults with moderate to severe plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy and for adults with active psoriatic arthritis (PsA)[1]

SKYRIZI IS THE ONLY 4 DOSE A YEAR BIOLOGIC FOR Ps & FOR PsA THAT OFFERS A SINGLE-DOSE PEN[1]

150 mg/mL SINGLE-DOSE PEN

NDC: 0074-2100-01

SUPPLIED AS: One 150 mg/mL pen.[1]

STORAGE: Refrigerate at 2 °C to 8 °C (36 °F to 46 °F), do not freeze or shake, and keep pen in original carton to protect from light.[1]

PREPARATION: Remove the carton from the refrigerator and allow to reach room temperature out of direct sunlight **(30 to 90 minutes)** without removing the pen from the carton.[1]

EASE OF USE CERTIFIED
Arthritis Foundation

The SKYRIZI Pen was awarded an Ease of Use certification from the Arthritis Foundation's independent lab testing, which included psoriatic arthritis patients.[2]

ALSO AVAILABLE IN A

150 mg/mL SINGLE-DOSE PREFILLED SYRINGE

NDC: 0074-1050-01

STORAGE: Requirements are the same as the 150 mg/mL pen.[1]

PREPARATION: Remove the carton from the refrigerator and allow to reach room temperature out of direct sunlight **(15 to 30 minutes)** without removing the prefilled syringe from the carton.[1]

Important Safety Information[1]

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see accompanying Full Prescribing Information or visit https://www.rxabbvie.com/pdf/skyrizi_pi.pdf

References: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc. **2.** Data on file, AbbVie Inc. Arthritis foundation ease of use certification. December 2021.

Skyrizi® risankizumab-rzaa

abbvie